Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Global Manufacturing of CAR T Cell Therapy

1 Jan 2017

Abstract excerpt

Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types. Chimeric antigen receptor T cells are generated by removing T cells from a patient's blood and engineering the cells to express the chimeric antigen receptor,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28344995
DOI: 10.1016/j.omtm.2016.12.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Global Manufacturing of CAR T Cell TherapyPMID 28344995Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trialSemantic proximity Read ↗

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read ↗

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.Semantic proximity Read ↗

CAR T Cell Therapy: A Versatile Living DrugSemantic proximity Read ↗

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myelomaSemantic proximity Read ↗

Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi ArabiaSemantic proximity Read ↗

Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T CellsSemantic proximity Read ↗

Four challenges to CAR T cells breaking the glass ceilingSemantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.